Vertex Pharma (VRTX) Tops Q3 EPS by 23c, provides guidance

Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.80, $0.23 better than the analyst estimate of $4.57. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.05 billion.

GUIDANCE:

Vertex Pharma sees FY2025 revenue of $11.9-12 billion, versus the consensus of $12.002 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
• Citi reiterates Buy rating on SanDisk with $2,100 target
• Citi raises EquipmentShare price target to $22, keeps Neutral